Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients.
The effect of hepatic dysfunction, defined as abnormal serum bilirubin level, on oral cyclosporin (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied, divided among patients with no (less than 1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0 to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by elimination rate constant and clearance, was delayed in patients with moderate hepatic dysfunction compared to those with no hepatic dysfunction (P less than .05). The volume of distribution, lag time for absorption, maximum serum concentration, and time at which the maximum concentration was achieved was not affected by hepatic function. These data indicate that patients with moderate hepatic dysfunction have delayed CSP or CSP metabolite elimination and may be at higher risk for developing CSP-related toxicity.
D000284:Administration, Oral; D001663:Bilirubin / Q000097:blood; D016026:Bone Marrow Transplantation; D003524:Cyclosporins / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism*
D003524:Cyclosporins; D001663:Bilirubin